| 微量白蛋白尿 (Microalbuminuria) | |
|---|---|
| 分类和外部资源 | |
| 医学专科 | 肾脏科 |
| ICD-9-CM | 791.0 |
| MedlinePlus | 003591 |
微量白蛋白尿(microalbuminuria)是用来描述白蛋白尿水平适度增加的医学术语。它发生在肾泄漏少量白蛋白(Human serum albumin)进入尿液里、换言之，即在肾脏肾小球的白蛋白有异常高的渗透性(Vascular permeability)。这个医学术语"微量白蛋白尿"现在KDIGO(Kidney Disease Improving Global Outcomes/肾脏病改善全球成果)计划不建议使用，并以"中度增加白蛋白尿"取代之。
病因
- 血管内皮功能障碍(endothelial dysfunction)的标志。
- 肾脏疾病预后的重要标志：
诊断
| 个人 | 底限 | 高限 | 单位 | |
|---|---|---|---|---|
| 24小时尿液收集 | 30[1] | 300[1] | mg/24h (每24小时的毫克白蛋白) | |
| 短时间尿液收集 | 20[1] | 200[1] | µg/min (每分钟的微克白蛋白) | |
| 定点白蛋白尿样本 | 30[2] | 300[2] | mg/L (每升尿液的毫克白蛋白) | |
| 定点白蛋白尿/肌酸酐比值 | 女人 | 3.5[3] | 25[3]or 35[3] | mg/mmol (每摩尔肌酸酐的毫克白蛋白) |
| 30[3] | 400[3] | μg/mg (每毫克肌酸酐的毫克白蛋白) | ||
| 男人 | 2.5[3]or 3.5[3] | 25[3]or 35[3] | mg/mmol | |
| 30[3] | 300[3] | μg/mg |
参见
注释
- ↑ 1.0 1.1 1.2 1.3 Page 90 in: Basic Skills in Interpreting Laboratory Data. ISBN 978-1-58528-180-0.
- ↑ 2.0 2.1 Person—microalbumin level (measured) at Australian Institute of Health and Welfare. 01/03/2005
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 [1] Thomas I. Justesen, Jens L. A. Petersen, Pia Ekbom, Peter Damm, Elisabeth R. Mathiesen. Albumin-to-creatinine ratio in random urine samples might replace 24-h urine collections in screening for micro- and macroalbuminuria in pregnant woman with type 1 diabetes. Diabetes Care. 2006-4, 29 (4): 924–925 [2019-02-13]. ISSN 0149-5992. PMID 16567839.
参考文献
- Abid O, Sun Q, Sugimoto K, Mercan D, Vincent JL. Predictive value of microalbuminuria in medical ICU patients: results of a pilot study. Chest. 2001, 120 (6): 1984–8. PMID 11742932. doi:10.1378/chest.120.6.1984.
- Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD. Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int. 2000, 58 (5): 2129–37. PMID 11044234. doi:10.1111/j.1523-1755.2000.00386.x.
- Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000, 355 (9200): 253–9. PMID 10675071. doi:10.1016/S0140-6736(99)12323-7.
- Lemley KV; Abdullah I; Myers BD; et al. Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int. 2000, 58 (3): 1228–37. PMID 10972685. doi:10.1046/j.1523-1755.2000.00223.x.
- Lièvre M; Marre M; Chatellier G; et al. The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group. Controlled Clinical Trials. 2000, 21 (4): 383–96. PMID 10913814. doi:10.1016/S0197-2456(00)00060-X.
- Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001, 345 (12): 870–8. PMID 11565519. doi:10.1056/NEJMoa011489.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., Suppl. 2013; 3: 1-150.